NCT00390429View on ClinicalTrials.gov

Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

July 31, 2002

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2012

Conditions
Lung CancerUnspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

docetaxel

Given IV

DRUG

erlotinib hydrochloride

Given orally

Trial Locations (1)

95817

University of California Davis Cancer Center, Sacramento

Sponsors
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Genentech, Inc.

INDUSTRY

collaborator

Aventis Pharmaceuticals

INDUSTRY

lead

University of California, Davis

OTHER